To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 30, 2018

Today's Rundown

Featured Story

Lilly seeks to quickly advance—and if needed kill—novel drugs to avoid ‘pile-on effect’ in hot targets

Eli Lilly is doubling down on novel mechanisms of action to steer clear of the “pile-on effect” seen in PD-1/PD-L1 and other hot targets. The Big Pharma wants to hightail novel approaches into the clinic and up to proof of concept before its rivals—and then kill off programs that fail to wow in phase 2.

Top Stories

With Pfizer's 'pipeline surprise,' there's a new kid on the ATTR block

Pfizer reported positive results from a phase 3 trial of tafamidis in transthyretin cardiomyopathy, a form of ATTR. The news drove down stocks for Alnylam and Ionis, both of which are developing drugs for hereditary forms of ATTR.

Cash reserves running low at KemPharm

Money is getting tight at KemPharm, with its liquid cash reserves—currently around $48.5 million—not expected to last through the first quarter of 2019.

[Sponsored] Highlighting Women Pioneers in Science & Medicine

As leaders in science and business, two high-profile female CEOs have been instrumental in advancing medical breakthroughs and are champions for issues that affect women around the world.

Gene therapy could promote healing in brain, spinal cord injuries

Switching on the LZK gene in mice with spinal cord injuries resulted in a smaller scar, which UT Southwestern researchers hope will improve recovery.

EuroBiotech Report—Ablynx fail, MorphoSys IPO, Redx trial halt, NMD financing and C4XD

In this week's EuroBiotech Report, Ablynx lupus drug fails midphase trial, MorphoSys files for $150 million IPO, Redx halts trial and more.

Chutes & Ladders—Gilead’s oncology clinical director jumps to Compugen

Gilead’s director of oncology clinical research jumped to Compugen as CMO, a longtime Teva executive will become Dr. Reddy's new COO, Astellas named a new head of ethics & compliance, plus more hirings, firings and retirings throughout the industry.

FiercePharmaAsia—Takeda’s Shire bid, WuXi AppTec’s and Aslan’s IPOs

Takeda is weighing a potentially difficult buyout bid for Shire that could be worth $52 billion, WuXi AppTec wins approval for its $900 million-plus IPO in Shanghai, Aslan Pharma aims to raise $86 million through an IPO on Nasdaq and more.

Resources

[Whitepaper] Compliance Certificate and Training for Life Sciences Professionals

4-day interactive educational program trusted by multi-national companies as part of their compliance training for employees. Explore legal, regulatory and ethical issues faced by pharmaceutical, biotech and medical device manufacturers operating globally. Visit event homepage for session topics.

[Whitepaper] Digitizing the Global Life Sciences Supply Chain: The Critical Role of Digital Transaction Management

Life science companies are experiencing a significant transformation in how they bring new products to market.

[Whitepaper] Medical Device Innovation: Are You Outrunning The Competition?

The competitive landscape in medical device R&D is tough. And simply investing in R&D is no guarantee for profitability. So how do you accelerate time-to-market?

[Whitepaper] Choosing the Right Solution: Improving the Site Feasibility Process

Selecting the right sites to conduct your clinical trials will determine the success or failure of meeting your enrollment goals.

[Whitepaper] How Do Sponsors Ensure Quality in Global Clinical Trials?

Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives.

[Webinar] Validating a 7 Day Membrane Filtration Sterility Test using Celsis®

Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols.

[Infographic] Evolution of Flexible Commercial Biologics Manufacturing

Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility.

[eBook] Developing Site-specifically Modified ADCs: Using a Chemoenzymatic Approach

Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology.

[Article] Optimizing titer and use of a specific enzyme for generating a fully processed antibody

Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing.

[Webinar] Within-Subject Clinical Trials: Intro to New Methods & Stat. Models

In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods.

Events

.